First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.| Read More JPost.com – The Jerusalem Post – All News from the Middle East, Israel, and the Jewish World | Read More in Virtual Jerusalem
Syria celebrates regime’s collapse while clashes flare near the Israeli border – analysis
Early bird flu season brings sharp rise in cases in Europe and North America
Tom Stoppard, acclaimed playwright of ‘Rosencrantz and Guildenstern,’ dies at 87
The forgotten victims of October 7 deserve a national memorial – opinion
Pro-Palestinian activists storm Manhattan Zara on Black Friday
Iranian hackers claim they left a heavy bouquet in Israeli nuclear scientist’s car
Dublin bid to rename ‘Herzog Park’ as ‘Free Palestine Park’ rejected by Ireland government
European diplomats say Israel veto on Palestinian Authority role stalls Gaza stabilization force
Watch: Kedumim residents celebrate with Perry family after elimination of Gideon’s killer
Trump announces: Venezuela airspace closed
Miracle: Near-murder in Samaria
Bnei Akiva names new year’s initiates ‘Amikam’Pro-Palestinian activists storm Manhattan Zara on Black Friday